title: The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: a randomised, double-blind, placebo-controlled trial.
abstract: Inflammatory markers such as interleukin (IL)-6 and tumour necrosis factor-alpha (TNF-α) are elevated in dialysis patients and can predict cardiovascular events and all-cause mortality. Endotoxin is an important source and also another marker of inflammation in patients with chronic kidney disease. The aim of this study was to evaluate the impact of oral probiotics on serum levels of endotoxemia and cytokines in peritoneal dialysis (PD) patients. The decline of residual renal function, peritonitis episodes, and cardiovascular events were also recorded. From July 2011 to June 2012, a randomised, double-blind, placebo-controlled trial was conducted in PD patients. The intervention group received one capsule of probiotics containing 10(9) cfu Bifobacterium bifidum A218, 10(9) cfu Bifidobacterium catenulatum A302, 10(9) cfu Bifidobacterium longum A101, and 10(9) cfu Lactobacillus plantarum A87 daily for six months, while the placebo group received similar capsules containing maltodextrin for the same duration. Levels of serum TNF-α, interferon gamma, IL-5, IL-6, IL-10, IL-17, and endotoxin were measured before and six months after intervention. 39 patients completed the study (21 in the probiotics group and 18 in the placebo group). In patients receiving probiotics, levels of serum TNF-α, IL-5, IL-6, and endotoxin significantly decreased after six months of treatment, while levels of serum IL-10 significantly increased. In contrast, there were no significant changes in levels of serum cytokines and endotoxin in the placebo group after six months. In addition, the residual renal function was preserved in patients receiving probiotics. In conclusion, probiotics could significantly reduce the serum levels of endotoxin, pro-inflammatory cytokines (TNF-α and IL-6), IL-5, increase the serum levels of anti-inflammatory cytokine (IL-10), and preserve residual renal function in PD patients.
authors.affiliation: 1 Graduate Institute of Clinical Medical Science, College of Medicine, China Medical University, 2 Yue-Der Road, Taichung 404, Taiwan.
authors.forename: I-K
authors.initials: IK
authors.lastname: Wang
authors.forename: Y-Y
authors.initials: YY
authors.lastname: Wu
authors.forename: Y-F
authors.initials: YF
authors.lastname: Yang
authors.forename: I-W
authors.initials: IW
authors.lastname: Ting
authors.forename: C-C
authors.initials: CC
authors.lastname: Lin
authors.forename: T-H
authors.initials: TH
authors.lastname: Yen
authors.forename: J-H
authors.initials: JH
authors.lastname: Chen
authors.forename: C-H
authors.initials: CH
authors.lastname: Wang
authors.forename: C-C
authors.initials: CC
authors.lastname: Huang
authors.forename: H-C
authors.initials: HC
authors.lastname: Lin
mesh_terms: D000328:Adult; D001644:Bifidobacterium / Q000502:physiology; D001691:Biological Therapy / Q000379:methods*; D016207:Cytokines / Q000097:blood*; D004311:Double-Blind Method; D019446:Endotoxemia / Q000517:prevention & control*; D004731:Endotoxins / Q000097:blood*; D005260:Female; D006801:Humans; D048191:Lactiplantibacillus plantarum / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D010919:Placebos / Q000008:administration & dosage; D019936:Probiotics / Q000008:administration & dosage*; D051437:Renal Insufficiency / Q000150:complications* / Q000628:therapy; D044967:Serum / Q000737:chemistry; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D004731:Endotoxins; D010919:Placebos
keywords: cytokines; endotoxin; inflammation; peritoneal dialysis; probiotics